Navigation Links
Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
Date:4/13/2009

SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413LA97352LOGO)

"The issuance of this production patent is another important milestone in strengthening the patent estate of our lead product candidate, fidaxomicin," said Michael N. Chang, Ph.D., President and CEO of Optimer. "We believe this patent and the issued polymorphic Form A patent, along with additional pending patent applications, will enhance our intellectual property protection for fidaxomicin."

Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under d
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , EAST HANOVER, N.J., Dec. 2 /PRNe... including a late-breaking presentation on Tasigna...ronic myeloid leukemia, demonstrate the strength o...the care of patients. ,, The new data, at the ...eeting and Exposition, highlight the company,s cur...
(Date:12/1/2009)..., , TEMECULA, Calif., Dec. 1 /PRNewswire-Fir...Bulletin Board: PSTX) announced today that it has ...f Chief Financial Officer, Treasurer and Corporate...ting CFO since 2008. Prior to joining Patient Saf...t Finance, Chief Financial Officer, Treasurer and ...
(Date:12/1/2009)..., , REDONDO BEACH, Calif., Dec. 1 /PRNewswire...ounces their Elective Single Embryo Transfer (eSET...entive for patients with good embryo quality and a...he chance of twins by transferring a single embryo... technology today is reducing the number of multip...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2GSK Advisory 3A Warehouse Theft 55192 1GSK Advisory 3A Warehouse Theft 55192 2American Lung Association in Minnesota 3A Motorists Can Get 85 Cents a Gallon E85 Fuel in Woodbury Minn 55189 1AMERIGROUP Corporation to Host Investor Day 55187 1
...ty of Hematology (ASH) and the American Society of... joint guideline on the use of,erythropoiesis-stim...late,the bone marrow to produce more red blood cel...oal of these guidelines is to inform clinicians wi...studies regarding the risks and,benefits of ESAs i...
...pplications for RNAi, WALTHAM, Mass., Oct. 22 Th...ld leader in serving science, has,collaborated wit...echnology,platform that expands applications for R...sciences research, including neuroscience, immunol...d Thermo Scientific Dharmacon(R),SMARTvector(TM) s...
Other Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research 2Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research 3
(Date:12/2/2009)...ising incidence of obesity could counter recent in... 2 (HealthDay News) -- The overall health of the U...cades, largely because people have quit smoking in...t soon be wiped out if the rising obesity rates am...rent trends in both smoking and obesity continue u...
(Date:12/2/2009)...hes now available, many more to come, NIH director... News) -- Thirteen stem cell lines have been adde...-funded research, and many more such lines will so...ced Wednesday. , These are the first additional...unded by the U.S. National Institutes of Health (N...
(Date:12/2/2009)...WHITE PLAINS, N.Y., Dec. 2 /PRNewswire-USNewswire/... their findings in blood cancer research at the an...ce in New Orleans December 4-8, 2009. ,, Throu...oma Society (LLS) experts, including Chief Medical...esident of Patient Services Hildy Dillon, and Vice...
(Date:12/2/2009)...PHILADELPHIA, Dec. 2 Independence ...nefits contract with Lincoln Financial Group. IBC ...or approximately 10,000 Lincoln Financial Group em... nation. The Lincoln plan offerings will include t...s. ,, "I know I speak for all of us at Independ...
(Date:12/2/2009)...Joseph Balboni loves sports. An avid tennis player...old insurance agent became increasingly frustrated...us, a degenerative eye disorder. Unable to return ... he faced the prospect of a corneal transplant to ... years ago, Balboni discovered an alternative trea...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Brandeis studies evaluate visionary approach to improving eyesight 2
... Infections during the first year of life are a ma...s of arthritis later in life, according to new res...he Annual Congress of the European League Against ...irst birthday had an increased likelihood of devel...
...he issue of selling kidneys. , A regulated system...tion to the growing shortage of kidneys for transp...ry at the University of Minnesota. , In many are...is the annual death rate for suitable transplant c...
...pedics, Inc., a,leader in orthopedic extremity imp...ecutives, William F. Warrender, Jr., John F. Walte...s. Their extensive background and,experience will ...les. He brings more than 25 years of sales, market...
...Certain single nucleotide polymorphisms (SNPs) wit...region are shown to be associated with juvenile id... of two independent cohorts presented today at EUL... genetic code), rs2104286, rs41295061 and rs115946...
... WASHINGTON, June 13 A team of professionals,fro...to Germany on Saturday,to work with the US Army,s ...ng their current rehabilitation practices. They wi...tation,services. The ERMC operates 15 ambulatory c...
... try to resolve remaining issues, TORONTO, June 1...pany,PreMD Inc. (TSX: PMD; Amex: PME) today announ... the U.S. Food and Drug Administration (FDA) in an...next 60 days PreMD and the FDA will work together ...
Other Medicine News:Health News:Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis 2Health News:What's wrong with selling kidneys? 2Health News:Three Industry Veterans Join Ascension Orthopedics 2Health News:Three Industry Veterans Join Ascension Orthopedics 3Health News:Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:PreMD Reports Further Positive Meetings with the FDA 2
Shepard Bipolar Forceps Straight
Shepard Bipolar Forceps Angled
McCullough Bipolar Forceps
Dean Tonsil Knife
Medicine Products: